AU2022337266A1 - Monospecific and bispecific antibodies and antigen binding fragments thereof - Google Patents

Monospecific and bispecific antibodies and antigen binding fragments thereof Download PDF

Info

Publication number
AU2022337266A1
AU2022337266A1 AU2022337266A AU2022337266A AU2022337266A1 AU 2022337266 A1 AU2022337266 A1 AU 2022337266A1 AU 2022337266 A AU2022337266 A AU 2022337266A AU 2022337266 A AU2022337266 A AU 2022337266A AU 2022337266 A1 AU2022337266 A1 AU 2022337266A1
Authority
AU
Australia
Prior art keywords
monospecific
antigen binding
binding fragments
bispecific antibodies
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022337266A
Other languages
English (en)
Inventor
Rekha Bansal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelmed Therapeutics Inc
Original Assignee
Novelmed Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelmed Therapeutics Inc filed Critical Novelmed Therapeutics Inc
Publication of AU2022337266A1 publication Critical patent/AU2022337266A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022337266A 2021-08-31 2022-08-31 Monospecific and bispecific antibodies and antigen binding fragments thereof Pending AU2022337266A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/462,795 2021-08-31
US17/462,795 US11981727B2 (en) 2021-08-31 2021-08-31 Monospecific and bispecific antibodies and antigen binding fragments thereof
PCT/US2022/075723 WO2023034842A2 (en) 2021-08-31 2022-08-31 Monospecific and bispecific antibodies and antigen binding fragments thereof

Publications (1)

Publication Number Publication Date
AU2022337266A1 true AU2022337266A1 (en) 2024-03-14

Family

ID=85386669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022337266A Pending AU2022337266A1 (en) 2021-08-31 2022-08-31 Monospecific and bispecific antibodies and antigen binding fragments thereof

Country Status (7)

Country Link
US (2) US11981727B2 (https=)
EP (1) EP4396226A4 (https=)
JP (1) JP2024545741A (https=)
CN (1) CN118475605A (https=)
AU (1) AU2022337266A1 (https=)
CA (1) CA3230258A1 (https=)
WO (1) WO2023034842A2 (https=)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ503033A (en) 1997-08-26 2003-01-31 Gliatech Inc Inhibition of complement activation using anti-properdin agents
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
US9745367B2 (en) 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
WO2008134430A1 (en) 2007-04-24 2008-11-06 Novelmed Therapeutics Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
CN101970002B (zh) 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
DK2262831T3 (en) 2008-03-03 2015-04-27 Novelmed Therapeutics Inc ANTI-Properdin ANTIBODIES
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
US20140127204A1 (en) 2010-09-03 2014-05-08 Novelmed Therapeutics, Inc. Anti-properdin antibodies
EP2544694B1 (en) * 2010-03-02 2018-10-31 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin
WO2013102123A2 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
CA2869477C (en) 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor c3 antibodies and uses thereof
US9243070B2 (en) 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
CA2887050A1 (en) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
AU2014370404A1 (en) 2013-12-24 2016-07-07 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
MX2019008827A (es) 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.

Also Published As

Publication number Publication date
EP4396226A2 (en) 2024-07-10
JP2024545741A (ja) 2024-12-11
US20250042981A1 (en) 2025-02-06
US11981727B2 (en) 2024-05-14
EP4396226A4 (en) 2025-08-13
CN118475605A (zh) 2024-08-09
US20230073274A1 (en) 2023-03-09
CA3230258A1 (en) 2023-03-09
WO2023034842A2 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
EP4010378A4 (en) ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
IL315254A (en) Human 3E10 antibodies, variants and antigen-binding fragments thereof
EP4483895A3 (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
EP3847196A4 (en) BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
AU2021383901A9 (en) Bispecific antibody and use thereof
IL291082A (en) Anti-vsig4 antibody or antigen-binding fragment and uses thereof
IL317175A (en) Novel anti-GPRC5D antibodies, bispecific antigen-binding molecules that bind GPRC5D and CD3, and uses thereof
EP4274851A4 (en) MONOCLONAL ANTI-GPRC5D ANTIBODIES AND USES THEREOF
IL308918A (en) Antibodies and bispecific binding proteins that bind OX40 and/or PD-L1
AU2021378575A9 (en) Anti-tspan8-anti-cd3 bispecific antibody and anti-tspan8 antibody
EP4161556A4 (en) METHODS FOR SELECTING ANTIBODY FRAGMENTS, RECOMBINANT ANTIBODIES PRODUCED THEREBY AND THEIR USE
CA3260354A1 (en) Monoclonal Antibodies Against SLC34A2 and Their Uses
EP4274852A4 (en) BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF
CA3250452A1 (en) ANTI-5T4 ANTIBODIES AND THEIR USES
EP4276113A4 (en) Antibody specifically binding to CD47 and antigen-binding fragment thereof
AU2022337266A1 (en) Monospecific and bispecific antibodies and antigen binding fragments thereof
IL317443A (en) Humanized antibodies or active parts thereof against cancer antigens
EP4237443A4 (en) ANTI-SARS-COV-2 ANTIGEN ANTIBODIES AND ASSOCIATED COMPOSITIONS AND METHODS
HK40095895A (en) Anti-ror1 antibodies and related bispecific binding proteins
HK40119832A (en) Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
HK40128075A (zh) 双特异性抗原结合分子及其应用
CA3289717A1 (en) Bispecific antigen binding molecule and use thereof
CA3285055A1 (en) Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof
HK40078970A (en) Anti-tmprss2 antibodies and antigen-binding fragments
AU2024217436A1 (en) Compositions including anti-wt-1 antibodies antigen binding fragments and uses thereof